Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase - PubMed (original) (raw)
Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase
D Zhang et al. Antimicrob Agents Chemother. 1994 Feb.
Abstract
A human immunodeficiency virus type 1 variant resistant to zalcitabine (2',3'-dideoxycytidine [ddC]) was selected by sequential passage in the presence of increasing concentrations of ddC in peripheral blood mononuclear cell cultures. A mutation causing a lysine-to-arginine substitution was noted in reverse transcriptase (RT) codon 65 of this ddC-selected virus. A cloned mutant virus with this codon 65 mutation was constructed by using a novel PCR approach for site-directed mutagenesis. Characterization of this virus confirmed that the RT Lys-65-->Arg substitution was necessary and sufficient for a fourfold increase in the ddC 50% inhibitory concentration, as well as for resistance to didanosine (2',3'-dideoxyinosine [ddI]). Lys-65-->Arg and virus resistance to ddC and ddI also developed during therapy in isolates from one ddC-treated patient and two ddI-treated patients. Recombinant-expressed codon 65 mutant RT enzyme was resistant to ddCTP and ddATP in cell-free polymerase assays. Results of mutant enzyme studies are consistent with Lys-65-->Arg leading to changes in binding of the triphosphate forms of these nucleoside analogs to the RT. These data have implications for future studies of ddC resistance, particularly those aimed at defining its clinical relevance.
Similar articles
- Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2',3'-dideoxycytidine 5'-triphosphate and other drugs.
Gu Z, Arts EJ, Parniak MA, Wainberg MA. Gu Z, et al. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2760-4. doi: 10.1073/pnas.92.7.2760. Proc Natl Acad Sci U S A. 1995. PMID: 7535930 Free PMC article. - Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.
Gu Z, Gao Q, Fang H, Salomon H, Parniak MA, Goldberg E, Cameron J, Wainberg MA. Gu Z, et al. Antimicrob Agents Chemother. 1994 Feb;38(2):275-81. doi: 10.1128/AAC.38.2.275. Antimicrob Agents Chemother. 1994. PMID: 7514855 Free PMC article. - Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine.
Gu Z, Gao Q, Li X, Parniak MA, Wainberg MA. Gu Z, et al. J Virol. 1992 Dec;66(12):7128-35. doi: 10.1128/JVI.66.12.7128-7135.1992. J Virol. 1992. PMID: 1279198 Free PMC article. - Perspectives on the molecular mechanism of inhibition and toxicity of nucleoside analogs that target HIV-1 reverse transcriptase.
Anderson KS. Anderson KS. Biochim Biophys Acta. 2002 Jul 18;1587(2-3):296-9. doi: 10.1016/s0925-4439(02)00092-3. Biochim Biophys Acta. 2002. PMID: 12084471 Review. - Site-directed mutagenesis of HIV reverse transcriptase to probe enzyme processivity and drug binding.
Beard WA, Wilson SH. Beard WA, et al. Curr Opin Biotechnol. 1994 Aug;5(4):414-21. doi: 10.1016/0958-1669(94)90051-5. Curr Opin Biotechnol. 1994. PMID: 7520785 Review.
Cited by
- Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase.
Wainberg MA, Brenner BG, Turner D. Wainberg MA, et al. Antimicrob Agents Chemother. 2005 May;49(5):1671-8. doi: 10.1128/AAC.49.5.1671-1678.2005. Antimicrob Agents Chemother. 2005. PMID: 15855480 Free PMC article. Review. No abstract available. - The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.
Parikh UM, Bacheler L, Koontz D, Mellors JW. Parikh UM, et al. J Virol. 2006 May;80(10):4971-7. doi: 10.1128/JVI.80.10.4971-4977.2006. J Virol. 2006. PMID: 16641288 Free PMC article. - Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2',3'-dideoxycytidine 5'-triphosphate and other drugs.
Gu Z, Arts EJ, Parniak MA, Wainberg MA. Gu Z, et al. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2760-4. doi: 10.1073/pnas.92.7.2760. Proc Natl Acad Sci U S A. 1995. PMID: 7535930 Free PMC article. - Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication.
Caliendo AM, Savara A, An D, DeVore K, Kaplan JC, D'Aquila RT. Caliendo AM, et al. J Virol. 1996 Apr;70(4):2146-53. doi: 10.1128/JVI.70.4.2146-2153.1996. J Virol. 1996. PMID: 8642636 Free PMC article. - Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years.
Winters MA, Shafer RW, Jellinger RA, Mamtora G, Gingeras T, Merigan TC. Winters MA, et al. Antimicrob Agents Chemother. 1997 Apr;41(4):757-62. doi: 10.1128/AAC.41.4.757. Antimicrob Agents Chemother. 1997. PMID: 9087484 Free PMC article. Clinical Trial.
References
- Nature. 1987 Apr 9-15;326(6113):610-3 - PubMed
- Antimicrob Agents Chemother. 1994 Feb;38(2):275-81 - PubMed
- J Clin Microbiol. 1988 Jul;26(7):1416-8 - PubMed
- Nucleic Acids Res. 1988 Aug 11;16(15):7351-67 - PubMed
- J Acquir Immune Defic Syndr. 1989;2(6):579-87 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources